|Assessment Status||Assessment process complete|
|Indication||For the treatment of symptomatic chronic heart failure with reduced ejection fraction.|
|Rapid review commissioned||05/07/2021|
|Rapid review completed||29/07/2021|
|Rapid review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of empagliflozin compared with the current standard of care.|
|Full pharmacoeconomic assessment commissioned by HSE||24/08/2021|
|Pre-submission consultation with Applicant||18/10/2021|
|Full submission received from Applicant||12/01/2022|
|Preliminary review sent to Applicant||28/02/2022|
|NCPE assessment re-commenced||28/03/2022|
|Factual accuracy sent to applicant||30/03/2022|
|NCPE assessment re-commenced||07/04/2022|
|NCPE assessment completed||28/04/2022|
|NCPE assessment outcome||The NCPE considers empagliflozin to be a cost-effective treatment for adults with symptomatic chronic heart failure with reduced ejection fraction and reimbursement is recommended*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement, December 2022.